TriangleRELY-30 (NCT02917083)
RELY-30 trial for Hodgkin's Lymphoma (NCT02917083). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
Hodgkin lymphoma is usually cured. When it keeps returning after chemotherapy, antibodies, and transplant, the choices thin out.
The idea: take the antibody that already targets Hodgkin cells, and bolt it onto the patient's own T cells.
Hodgkin cells carry a marker called CD30. Antibody drugs against it help but rarely cure. Here, T cells from the patient's blood receive a gene that mounts the anti-CD30 antibody on their surface, so each cell hunts on its own. One infusion, after chemotherapy clears room.
In forty-one heavily treated patients at two centers, side effects were mostly on blood counts, and after fludarabine-based chemotherapy, seven in ten responded, most completely.
RELY-30, at Baylor, led by Carlos Ramos, now tests higher doses. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.